ALDX

Reproxalap

Dry Eye Disease

Stage (next event)

Expected Date

Phase 3 To be Initiated

Q4 2020

Catalyst Info & Data Links

TITLE: Reproxalap for Dry Eye Disease Phase 3 To be Initiated

  • Clinical Trial (NCT03879863) The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 3 To be Initiated


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q4 2020 


PRIOR DATA/EVENTS

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION

  • RASP effect inflammation signaling via covalent binding to proteins, including receptors and enzymes.

  • RASP-protein adducts directly influence the function of proteins, leading to activation of intracellular inflammatory factors, including NF-kB, an important mediator in the inflammatory response.

  • In addition, RASP-protein adducts bind to Scavenger Receptor A, which also initiates pro-inflammatory signaling and leads to the formation of antibodies against the adducted protein, at least in part explaining the presence of host-directed antibodies in autoimmune diseases such as rheumatoid arthritis

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

ALDX Presents Positive Ph3 Data in Allergic Conjunctivitis

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon